Research Reports

Key takeaways

Board expanded from 10 to 11 authorized directors on April 10, 2026.

Robert S. Field elected as independent director under NYSE standards, effective April 16, 2026.

Field compensated per director program with initial RSU grant; proxy filed March 6, 2026.

Field is Principal and Managing Member of ηMed Capital Management LLC, focused on U.S. healthcare services.

No committee assignments or related arrangements/transactions disclosed.

Appointment followed Board-led search with shareholder input including Sessa Capital.

Full analysis

Humana's Board expansion and election of Robert S. Field as an independent director reflects ongoing refreshment efforts informed by shareholder engagement, including input from Sessa Capital's John Petry. Field brings over two decades of healthcare investment experience from ηMed Capital Management LLC, Luxor Capital, McKinsey & Company, and Vinson & Elkins LLP, offering expertise in investment evaluation, risk oversight, capital allocation, and healthcare regulatory dynamics. Chairman Kurt J. Hilzinger highlighted Field's investor perspective as valuable for executing Humana's strategy to drive profitable growth and shareholder value. No committee roles or special arrangements are set, with compensation aligning to the standard program detailed in the March 6, 2026 proxy statement.

HUM · Humana Inc.

Summary

Key takeaways

Full analysis